hes1-protein--human and Small-Cell-Lung-Carcinoma

The Notch signaling pathway has different roles in many human neoplasms, being either tumor-promoting or anti-proliferative. In addition, Notch signaling in carcinogenesis can be tissue dependent. The aim of the current study is to elucidate the relation between Notch1 protein expression in lung cancer cells and the following Notch related proteins: Hes1, c-Myc, Jagged1 and Jagged2.. Notch1 and its related proteins were detected in human lung cancer cell lines and in 54 surgically resected different lung carcinoma tissues. Then, we used small interfering RNA (siRNA) technology, to down-regulate the expression of Notch1 in H69AR and SBC3 small cell lung carcinoma (SCLC) cells. Also, we transfected venus Notch1 intracellular domain (v.NICD) plasmid into human SCLC lines; H69.. The expression of Hes1, c-Myc and Jagged2 is affected by Notch1 in SCLC.. There is a strong association between the expression of Notch1 protein and the expression of Hes1, c-Myc and Jagged2 proteins, which could aid in better understanding tumorigenesis in SCLC.

Topics: A549 Cells; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Jagged-1 Protein; Jagged-2 Protein; Lung Neoplasms; Proto-Oncogene Proteins c-myc; Receptor, Notch1; Receptors, Notch; RNA, Small Interfering; Signal Transduction; Small Cell Lung Carcinoma; Transcription Factor HES-1

The aim was to analyse the tumor expression of Notch1, Hes1, Ascl1, and DLL3 in Small-Cell Lung Cancer (SCLC) and each such biomarker's potential association with clinical characteristics and prognosis after platinum-doublet chemotherapy (PDCT).. The protein expression of the biomarkers was evaluated using immunohistochemistry. Patients were categorized according to their sensitivity to first line PDCT: with a Progression-free survival (PFS) ≥ 3 months after completion of treatment considered "sensitive" and < 3 months after completion of treatment considered "refractory". PFS and overall survival were computed using Kaplan-Meier curves with 95% confidence interval.. The study included 46 patients, with 21 and 25 of the patients having "sensitive" and "refractory" disease, respectively. The majority of patients had a high DLL3 expression (n = 38), while a minority had Notch 1-high expression (n = 10). The chi-square test showed that there was a statistically significant negative association between Notch1 and Ascl1 expression (p = 0.013). The overall survival for patients with Notch1- high vs. low expression was 8.1 vs. 12.4 months, respectively (p = 0.036). Notch1 expression was an independent prognostic factor in the multivariate analysis (p = 0.02). No other biomarker showed any prognostic impact in this highly selected SCLC cohort. DLL3 is highly expressed in the majority of advanced staged SCLC cases, as expected. In the same patient population, Notch1 expression might have a potential prognostic implication, by driving a non-neuroendocrine differentiation process. Given the small number of cases with Notch1 high expression, the results of this study needs to be confirmed on a larger cohort.

Topics: Aged; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Platinum; Prognosis; Receptor, Notch1; Small Cell Lung Carcinoma; Survival Analysis; Transcription Factor HES-1; Treatment Outcome

Small-cell lung cancer (SCLC) is a highly malignant type of lung cancer with no effective second-line chemotherapy drugs. Arsenic trioxide (As

Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Animals; Arsenic Trioxide; Calcium-Binding Proteins; Cell Line, Tumor; Cell Proliferation; Collagen; Down-Regulation; Drug Combinations; Human Umbilical Vein Endothelial Cells; Humans; Intercellular Signaling Peptides and Proteins; Laminin; Lentivirus; Lung Neoplasms; Male; Mice, Nude; Proteoglycans; Receptors, Notch; Signal Transduction; Small Cell Lung Carcinoma; Transcription Factor HES-1; Up-Regulation; Xenograft Model Antitumor Assays

Insulinoma-associated protein 1 (INSM1) is expressed exclusively in embryonic developing neuroendocrine (NE) tissues. INSM1 gene expression is specific for small-cell lung cancer (SCLC), along with achaete-scute homolog-like 1 (ASCL1) and several NE molecules, such as chromogranin A, synaptophysin, and neural cell adhesion molecule 1. However, the underlying biological role of INSM1 in lung cancer remains largely unknown. We first showed that surgically resected SCLC samples specifically expressed INSM1. Forced expression of the INSM1 gene in adenocarcinoma cell lines (H358 and H1975) induced the expression of ASCL1, brain-2 (BRN2), chromogranin A, synaptophysin, and neural cell adhesion molecule 1; in contrast, knockdown of the INSM1 gene by siRNA in SCLC (H69 and H889) decreased their expression. However, forced/knockdown expression of ASCL1 and BRN2 did not affect INSM1 expression. A chromatin immunoprecipitation study revealed that INSM1 bound to the promoter region of the ASCL1 gene. A xenotransplantation assay using tet-on INSM1 gene-transfected adenocarcinoma cell lines demonstrated that INSM1 induced NE differentiation and growth inhibition. Furthermore, we found that INSM1 was not expressed in non-small-cell lung cancer and some SCLC cell lines expressing Notch1-Hes1. By forced/knockdown expression of Notch1 or Hes1 genes, we revealed that Notch1-Hes1 signaling suppressed INSM1, as well as ASCL1 and BRN2. INSM1, expressed exclusively in SCLC, is a crucial regulator of NE differentiation in SCLCs, and is regulated by the Notch1-Hes1 signaling pathway.

Topics: Adenocarcinoma; Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Gene Knockdown Techniques; Heterografts; Homeodomain Proteins; Humans; Lung Neoplasms; Mice, Inbred Strains; Neoplasm Proteins; Neoplasm Transplantation; Neuroendocrine Cells; POU Domain Factors; Receptor, Notch1; Repressor Proteins; Signal Transduction; Small Cell Lung Carcinoma; Transcription Factor HES-1

Delta-Like1 (DLL1) can combine with Notch receptor and activate the Notch signal pathway, then made a decision to cell differentiation and regulate the development of many tissues. It is proved that DLL1 was highly correlated with tumor'growth and differentiation, our previously study showed that DLL1 was associated with MDR in small cell lung cancer (SCLC). The aim of this study is to furtherly investigate the role of DLL1 gene in small cell lung multi-drug resistance.. Firstly, the analysis of qRT-PCR and Western blot were used to study differential expression of DLL1 from mRNA and protein levels in both the H69 and H69AR cell lines. Then, we developed a stably DDL1 overexpressing H69AR-eGFP-DLL1 subline, by transfection with DLL1-pIRES2-EGFP. Moreover, the sensitivities of cells to chemotherapy drugs such as ADM, DDP, VP-16 were detected by CCK8 assay. The change of cell cycle and apoptosis rate were detected by flow cytometry.. The expression of DLL1 was significantly decreased in H69AR cells than that in the H69 cells. The sensitivities of H69AR cells to chemotherapy drugs were increased when up-regulated the expression of DLL1, enforced DLL1 expression increased cell apoptosis and the cell cycle arrest in G0/G1 and S phase in H69AR cells, the expression of downstream genes HES1 and HEY1 were increased after transfected with DLL1-pIRES2-EGFP.. Our results suggest that overexpression of DLL1 in small cell lung cancer may increase the sensitivity of cells to chemotherapeutic agents. DLL1 influence drug resistance of small cell lung cancer through activating transcription of downstream genes HES1 and HEY1.. 背景与目的 DLL1（Delta-Like1）与Notch受体结合激活Notch信号通路，从而决定细胞的分化，并调控多种组织的生长发育。已有研究报道DLL1与肿瘤的生长、分化密切相关。前期基因芯片发现DLL1与小细胞肺癌的耐药性相关，本研究旨在进一步探讨DLL1在小细胞肺癌多药耐药中的作用。方法 首先通过QRT-PCR和Western blot从基因和蛋白水平检测化疗敏感细胞株H69及多药耐药细胞株H69AR中DLL1的差异表达；转染DLL1-pIRES2-EGFP表达质粒上调H69AR细胞中的DLL1的表达，构建稳定转染的过表达细胞株H69AR-eGFP-DLL1 ，通过CCK8检测细胞对各种化疗药物（ADM, DDP, VP-16）的敏感性变化，流式细胞仪检测细胞周期及凋亡的变化。结果 DLL1在化疗敏感细胞H69中的表达明显高于H69AR，过表达H69AR中DLL1的表达能够增加细胞对化疗药物的敏感性，促进细胞的凋亡，细胞周期发生G0/G1期及S期阻滞，上调DLL1增加其下游基因HES1、HEY1的表达。结论 在小细胞肺癌中上调DLL1的表达可能增加细胞对化疗药物的敏感性，DLL1通过肿瘤细胞间的相互作用激活HES1、HEY1等下游基因，影响小细胞肺癌的多药耐药。

Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Calcium-Binding Proteins; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Etoposide; Green Fluorescent Proteins; Homeodomain Proteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Proteins; Microscopy, Fluorescence; Reverse Transcriptase Polymerase Chain Reaction; Small Cell Lung Carcinoma; Transcription Factor HES-1; Up-Regulation

To clarify the biological differences between small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC), we investigated the expression of two bHLH type transcription factors, human achaete-scute homolog 1 (hASH1) and hairy/enhancer of split 1 (HES1), which positively and negatively regulate the neuroendocrine differentiation of respiratory epithelial cells, respectively. Eighty-eight formalin-fixed and paraffin-embedded pulmonary carcinomas (32 SCLC, 32 LCNEC, 14 adenocarcinomas, and 10 squamous cell carcinomas) and 14 SCLC and 1 LCNEC derived cell lines were used. hASH1 and HES1 mRNA were detected using a highly sensitive in situ hybridization method with digoxigenin-labeled cRNA probes and biotinylated tyramide. The staining results were scored from 0 to 12 by multiplying the staining intensity by the percentage of positive tumor cells. The mean staining score of hASH1 mRNA was significantly higher in SCLC than in LCNEC (p<0.01); conversely, that of HES1 mRNA was lower in SCLC than in LCNEC (p<0.01). These findings reveal that SCLC more strongly expresses the neuroendocrine phenotype, while LCNEC shows characteristics more similar to the ciliated epithelium phenotype, suggesting that the biological characteristics of these two tumors are different.

Topics: Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Large Cell; Cell Line, Tumor; Cilia; Diagnosis, Differential; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; In Situ Hybridization; Lung Neoplasms; Neuroendocrine Cells; Proteomics; Respiratory Mucosa; RNA, Messenger; Small Cell Lung Carcinoma; Transcription Factor HES-1; Vascular Endothelial Growth Factor A

To investigate the status of Notch signaling pathway in small cell lung cancer (SCLC).. Expression plasmids of pEFBOS-NIC-MYC and pEFBOS-neo were transfected into NCI-H446 cells. Stably transfected cell lines were selected and their growth rates were examined by MTT method. Expression of downstream genes along the Notch signaling pathway were studied by RT-PCR. Protein expression of euroendocrine markers of CgA and NSE were detected by Western blot analysis and immunocytochemistry.. The expression of HES1 was increased in the pEFBOS-NIC-MYC group, but the expression of hASH in the pEFBOS-NIC-MYC group was decreased significantly. The transfected cells with pEFBOS-NIC-MYC plasmid showed a significantly slower growth rate compared with that of two control groups (P < 0.05, Student's t-test). Immunocytochemistry of NSE showed that PUs in the NIC transfected group, sham group and negative control group were 7.21 ± 0.59, 28.25 ± 1.46, 30.57 ± 1.31 respectively, the former one was smaller than the values of the latter two significantly (P < 0.01). Western blot analysis showed the grave scales of CgA in NIC transfected group and sham group to be 0.54 ± 0.03 and 0.99 ± 0.05 respectively (grave scales of the negative control was set as 1.00), the former one significantly smaller than that of the other two groups (P < 0.01). The grave scales of NSE in the NIC transfected group and sham group were 0.43 ± 0.02 and 1.07 ± 0.09 respectively (grave scales of the negative control was set as 1.00) and the former one was significantly smaller than the other two groups (P < 0.01).. Notch signaling pathway regulates SCLC cells through its inhibitory effect on hASH1 transcription via HES1 along with an expression inhibition of neuroendocrine markers in SCLC.

Topics: Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Cell Proliferation; Chromogranin A; Homeodomain Proteins; Humans; Lung Neoplasms; Phosphopyruvate Hydratase; Plasmids; Receptor, Notch1; Recombinant Proteins; Signal Transduction; Small Cell Lung Carcinoma; Transcription Factor HES-1; Transfection